BioCryst Swings to $37.9M Third-Quarter Profit
BCRX sits 37% above its 52-week low of $6.23.
Summary
BioCryst posted third-quarter net income of $37.9 million, a swing to profit for the quarter, on revenue of $180.3 million and earnings of 14 cents per share. That is a sharp reversal from the prior baseline, when the company reported a $721.8 million net loss in Q1 driven largely by a non-cash charge tied to the Astria Therapeutics acquisition. The profit lands as ORLADEYO momentum builds: Japan's MHLW approved the drug for children aged 2 to under 12 in August, and the FDA cleared the 150 mg oral pellet formulation for adults and adolescents in October. Those two approvals widen the label and give the franchise more room to grow, which is what the quarter's bottom line reflects. Looking ahead, the company sees 2026 revenue of $715 million to $730 million, including 2026 ORLADEYO revenue of $625 million to $645 million.
At the time of this announcement, BCRX was trading at $8.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $6.23 to $11.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.